Pharmacological and Toxicological Threshold of Bisammonium Tetrakis 4-(<i>N</i>,<i>N</i>-Dimethylamino)pyridinium Decavanadate in a Rat Model of Metabolic Syndrome and Insulin Resistance

<div>Effective dose 50 analysis (ED<sub>50</sub>). The figure represents the percentage of glucose level reduction ≤130 mg/dL by administration of V10-DMAP. The hyperglycemic Long–Evans rats (<svg height="8.32035pt" id="M8" style="vertical-align:-0.2063999pt" version="1.1" viewbox="-0.0498162 -8.11395 27.8368 8.32035" width="27.8368pt" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><g transform="matrix(.013,0,0,-0.013,0,0)"><path d="M495 86L479 114C446 82 419 66 409 66C401 66 401 72 406 97C420 166 436 231 453 297C489 435 454 448 428 448C406 448 384 439 354 422C305 394 222 327 161 247H159L183 345C200 415 194 448 173 448C143 448 82 410 23 351L38 325C64 349 95 371 105 371C111 371 116 365 109 336L25 -4L31 -12C50 -4 77 3 107 9C119 69 132 122 145 168C197 254 321 381 370 381C387 381 393 374 378 305L329 95C309 17 320 -12 345 -12C372 -12 430 19 495 86Z" id="g113-111"></path></g><g transform="matrix(.013,0,0,-0.013,10.158,0)"><path d="M535 323V373H52V323H535ZM535 138V188H52V138H535Z" id="g117-34"></path></g><g transform="matrix(.013,0,0,-0.013,21.421,0)"><path d="M153 550H386L412 615L406 623H120L82 318C104 327 142 338 184 338C294 338 347 275 347 187C347 112 305 39 221 39C160 39 119 71 97 89C88 97 80 96 71 90C59 80 50 67 49 57C48 45 52 36 66 23C80 9 123 -12 169 -12C221 -11 288 15 342 59C403 109 431 165 431 225C431 308 366 395 238 395C212 395 165 379 127 364L153 550Z" id="g113-54"></path></g></svg>/group) were given with dosages of 0.0, 2.5, 5.0, 7.5, 10.0, and 20 <i>µ</i>mol of V10-DMAP for four weeks. The Long–Evans rats were alloxan-induced hyperglycemic (150 mg/kg). Mean glucose before V10-DMAP administration was ≈300 mg/dL.</div>

Bioinorganic Chemistry and Applications

fig1

Figure 1

Figure 1: Pharmacological and Toxicological Threshold of Bisammonium Tetrakis 4-(<i>N</i>,<i>N</i>-Dimethylamino)pyridinium Decavanadate in a Rat Model of Metabolic Syndrome and Insulin Resistance 

Figure 1 | Pharmacological and Toxicological Threshold of Bisammonium Tetrakis 4-(N,N-Dimethylamino)pyridinium Decavanadate in a Rat Model of Metabolic Syndrome and Insulin Resistance 